Feedback / Questions
efizonerimod (MEDI6383) - AgonOx, AstraZeneca
Imfinzi (durvalumab) - AstraZeneca, BMS
AstraZeneca: Q1 FY 2016 Update
(AstraZeneca)
-
Apr 30, 2016 -
Anticipated top-line data from P1 trial (NCT02221960) of durvalumab + MEDI6383 for advanced malignancies in 2018
Anticipated P1 data
•
Oncology
https://www.astrazeneca.com/content/dam/az/press-releases/2016/Clinical_trials_appendix_Q1_2016_update.pdf
Apr 30, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious